About this trial
The study is a prospective cohort that evaluates the clinical and immune-metabolic variables that may be linked to the risk and severity of the infection or even hospitalization or death in patients infected with the Mpox virus in Brazil. The expectation is to include at least 80 patients over six months, with a follow-up of 90 days from inclusion, through contact via decentralized visits.
Eligibility criteria
Qualifiers
Men and women aged ≥ 18 years with confirmed MPOX infection.
Disqualifiers
Inability to provide informed consent;
Patient who, judging by the study team, does not have a condition for decentralized follow-up
Trial design
Treatments tested in this trial
- Viral genomic
- Untargeted Metabolomics
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Hospital Israelita Albert Einstein
Lead sponsor
Ministry of Health, Brazil
Collaborator
Source ClinicalTrials.gov